Ocular Therapeutix, Inc.OCULNASDAQ
Loading
EV to Sales HistoryNormalizing
Percentile Rank38
3Y CAGR+108.2%
5Y CAGR-13.0%
Studio
Year-over-Year Change

Enterprise value to sales ratio

3Y CAGR
+108.2%/yr
vs -51.3%/yr prior
5Y CAGR
-13.0%/yr
Recent acceleration
Acceleration
+159.5pp
Accelerating
Percentile
P38
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
3 yr
Consecutive growthNormalizing
PeriodValueYoY Change
202531.18+91.9%
202416.25+289.8%
20234.17+20.6%
20223.46-64.8%
20219.82-84.3%
202062.52+43.8%
201943.47-29.3%
201861.52+13.0%
201754.46-46.0%
2016100.91-